info@seagull-health.com
SeagullHealth
语言:
search
new
Indications for Vigabatrin (Sabril)
502
Article source: Seagull Pharmacy
Nov 14, 2025

Vigabatrin (Sabril) is an antiepileptic drug commonly used to treat specific types of seizures, particularly in cases where other treatments have shown poor efficacy. Understanding its indications, dosage forms/characteristics, and proper storage methods is crucial for ensuring drug effectiveness and patient safety.

Indications for Vigabatrin (Sabril)

Refractory Complex Partial Seizures (CPS)

Vigabatrin is indicated as adjunctive therapy for patients aged 2 years and older with refractory complex partial seizures.

These patients must have tried multiple other treatment regimens with inadequate results, and the potential benefits of treatment must outweigh the risk of vision loss.

It is important to note that vigabatrin is not recommended as first-line therapy for complex partial seizures.

Infantile Spasms

Vigabatrin may be used as monotherapy for infantile spasms in infants aged 1 month to 2 years.

It should only be used when a physician assesses that the potential benefits of treatment far outweigh the risk of vision loss.

Dosage Forms and Characteristics of Vigabatrin (Sabril)

Tablets

Strength: Each tablet contains 500 mg of vigabatrin.

Appearance: White, film-coated, oval, biconvex tablets with a score line on one side and the engraving "OV111" on the other side.

Powder for Oral Solution

Strength: Each sachet contains 500 mg of white to off-white granular powder.

Reconstitution: For administration, the powder must be mixed with water to form a solution with a concentration of 50 mg/mL.

Solution Quality: The reconstituted solution should be clear and colorless. If turbidity or particles are present, the solution must be discarded.

Storage Methods for Vigabatrin (Sabril)

Storage Conditions

Both vigabatrin tablets and powder should be stored at room temperature between 20°C and 25°C (68°F and 77°F), and protected from moisture and direct sunlight.

Precautions for Reconstitution and Administration

Mixing Requirements: The powder must be mixed only with cold or room-temperature water; no other liquids should be used.

Dosing Accuracy: A dedicated oral syringe (3 mL or 10 mL) provided by the pharmacy must be used to accurately measure the dose during reconstitution. The use of household teaspoons or tablespoons is strictly prohibited, as incorrect dosing may affect efficacy or increase the risk of side effects.

Immediate Use: The reconstituted solution should be administered immediately. Any unused portion must be discarded and cannot be stored or reused.

Safety Warnings

Keep vigabatrin out of the reach of children to prevent accidental ingestion.

After each dose administration, the oral syringe and mixing cup should be cleaned promptly to maintain hygiene.


Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Recommended Articles
How to Use Repotrectinib (Augtyro)
Repotrectinib (Augtyro) is a novel kinase inhibitor that received its first approval in the United States in 2023. This medication is primarily indicated for the treatment of ROS1-positive non-small c...
Indications for Repotrectinib (Augtyro)
Repotrectinib (Augtyro) is an innovative kinase inhibitor that received its first approval from the U.S. Food and Drug Administration (FDA) in 2023. As a next-generation targeted therapy, repotrectini...
How to Purchase Repotrectinib (Augtyro)
Repotrectinib (Augtyro) is a next-generation kinase inhibitor and an important targeted medication for the treatment of ROS1-positive non-small cell lung cancer (NSCLC) and NTRK gene fusion-positive s...
What Are the Side Effects of Rasagiline (Azilect)?
Rasagiline (Azilect) is a selective and irreversible monoamine oxidase type B (MAO-B) inhibitor, approved for the treatment of Parkinson's disease. While this medication effectively improves motor...
How to Purchase Teneligliptin Hydrobromide/Canagliflozin Combination Tablets (Canalia)
Teneligliptin Hydrobromide/Canagliflozin Combination Tablets (Canalia) is a dual-target (DPP-4 and SGLT2) fixed-dose combination preparation developed by Mitsubishi Tanabe Pharma (Japan). It demonstra...
Indications for Teneligliptin Hydrobromide/Canagliflozin Combination Tablets (Canalia)
Teneligliptin Hydrobromide/Canagliflozin Combination Tablets (Canalia) is a dual-mechanism antidiabetic fixed-dose combination preparation developed by Mitsubishi Tanabe Pharma (Japan) and co-promoted...
Precautions for Administration of Teneligliptin Hydrobromide/Canagliflozin Combination Tablets (Canalia)
Teneligliptin Hydrobromide/Canagliflozin Combination Tablets (Canalia) is a fixed-dose combination preparation of a DPP-4 inhibitor and an SGLT2 inhibitor developed by Mitsubishi Tanabe Pharma (Japan)...
Procurement Channels for Enasidenib
Enasidenib is a targeted medication for the treatment of relapsed or refractory acute myeloid leukemia (AML). Its rational use is of crucial importance to patients. Due to the specific nature of this ...
Related Articles
Dosage and Administration, Recommended Dosage of Capmatinib (Tabrecta)
Capmatinib (Tabrecta) is a highly selective MET inhibitor, offering a precision treatment option for patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation...
What Are the Indications for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a targeted therapy medication that plays an important role in the treatment of non-small cell lung cancer associated with specific gene mutations. As a MET kinase inhibitor, i...
What Are the Purchase Channels for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a highly selective MET inhibitor that has demonstrated significant efficacy in patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutat...
Adverse Reactions of Ivosidenib (Tibsovo)
Ivosidenib (Tibsovo) is an isocitrate dehydrogenase 1 (IDH1) inhibitor, primarily indicated for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and cholangiocarcinoma...
What Are the Precautions for Using Ivosidenib (Tibsovo)?
Ivosidenib (Tibsovo) is a targeted therapy medication primarily indicated for the treatment of patients with malignant hematologic diseases harboring specific gene mutations.What Are the Precautions f...
Dosage and Administration, Recommended Dosage of Ivosidenib (Tibsovo)
Ivosidenib (Tibsovo) is a targeted isocitrate dehydrogenase 1 (IDH1) inhibitor that demonstrates significant value in the treatment of malignant tumors with specific gene mutations.Dosage and Administ...
What Are the Indications for Ivosidenib (Tibsovo)?
Ivosidenib (Tibsovo) is an oral isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with various malignant tumors harboring specific IDH1 gene mutations. By inhibiting the activity of m...
What Are the Purchase Channels for Ivosidenib (Tibsovo)?
Ivosidenib (Tibsovo) is an important targeted therapy drug against IDH1 mutations, demonstrating significant efficacy in diseases such as acute myeloid leukemia and cholangiocarcinoma. For patients in...
New Drugs
Infigratinib(Truseltiq)
Infigratinib(Truseltiq)
Treatment of previously treated, unresectable locally advanced or metastatic...
Opicapone(Ongentys)
Opicapone(Ongentys)
Adjunctive treatment to levodopa/carbidopa for reducing "off" episodes in...
Deflazacort(Emflaza)
Deflazacort(Emflaza)
Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and...
Faricimab-svoa(Vabysmo)
Faricimab-svoa(Vabysmo)
Treatment of neovascular age-related macular degeneration, diabetic macular...
Counselling Service
Global Drug Search
Clinical Research Recruitment
Overseas Medical Treatment
Remote Consultations
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Submit
Business
  • Core products
  • Antitumor drugs
  • General drug
  • Antiviral drugs
  • Biological agents
Contact Us 
  • mailbox:info@lucius.la
Welcome to consult
ucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved